Viatronix awarded Frost & Sullivan European medical imaging emerging
company of the year
8 October 2009
Frost & Sullivan has awarded the European Medical Imaging Emerging
Company of the Year Award in the radiology applications market to
Viatronix for its innovative 3D computer imaging technologies for
"Despite being a young company, Viatronix has shown dedication to
both developing and distributing high-end, organ-specific 3D clinical
solutions, while advancing its ability to address changing market
trends," says Frost & Sullivan Research Analyst Gideon Praveen Kumar.
"The company has emerged as a leader in the 3D imaging market in
Europe as a result of recent high profile partnerships and its active
engagement with the medical community through participation in clinical
trials and physician training programs."
Since its inception, the company has strived to offer efficient
diagnostic solutions in areas such as colon cancer screening, cardiac
analysis and vascular analysis. Through its innovative, cost- effective
offerings that reduce read time, Viatronix applications optimize the
utilization of CT scanners.
"Grasping the potential offered by the fast growing PACS market, the
Company has added a robust PACS interface to its clinical applications,
besides offering software-only solutions," says Kumar. "Viatronix has,
therefore, not only tapped into the trend of offering advanced
visualization technologies through PACS, but has also successfully kept
itself at the forefront of developing market trends for end users to
turn to high-end, organ-specific clinical solutions as opposed to
general purpose 3D imaging."
In 2005, Viatronix entered into a partnership with Eastman Kodak
Company (now known as Carestream), a global leader in advanced
healthcare products. The company successfully integrated its V3D-Colon
application into the CARESTREAM PACS System, allowing Viatronix to
leverage the sales and marketing potential of Carestream to reach an
extensive customer base.
Viatronix also entered into separate agreements with iCAD Inc., and
Medicsight PLC regarding the integration of colon CAD. The Company has
also signed an agreement with Visage Imaging Inc., for the distribution
of it V3D-Colon platform.
"As the medical imaging world moves from a 2D arena to 3D arena,
Viatronix's primary marketing efforts have been to sponsor and offer
educational programs to radiologists," remarks Kumar. "Along with
additional on-site training rendered to physicians, these educational
programmes have made the technological barrier as simple as possible for
In Dec. 2003 in the landmark clinical trial published in the New
England Journal of Medicine that put virtual colonoscopy on the
world map and for the first time showed a high degree of sensitivity and
specificity, the Viatronix V3D-Colon platform was the only platform
Subsequent to the 2003 clinical trial, the Viatronix V3D-Colon
product has been used in many clinical trials in Europe and the US
Viatronix V3D-Colon remains the only module on the market with a large
number of clinical trials under its belt with more on their way.
The base 3D visualization workflow that has been developed by
Viatronix is now being utilized into developing different organ-specific
clinical applications in a cost-effective manner. The company is
currently focused on the roll out of its V3D-Cardiac module which is
expected to be another industry leading product.
"Viatronix enjoys a competitive edge by having similar workflows and
a simple look and feel across all of its products," concludes Kumar.
"Also, by providing software-only, organ-specific modules, Viatronix has
gained an aggressive advantage over competitors who either require
specific hardware for their applications and/or require the end user to
purchase a base module before being able to acquire organ specific
Bookmark this page